Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Total Debt (2021 - 2025)

Historic Total Debt for Indivior Pharmaceuticals (INDV) over the last 5 years, with Q3 2025 value amounting to $322.0 million.

  • Indivior Pharmaceuticals' Total Debt changed N/A to $322.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $322.0 million, marking a year-over-year change of. This contributed to the annual value of $333.0 million for FY2024, which is 3875.0% up from last year.
  • Latest data reveals that Indivior Pharmaceuticals reported Total Debt of $322.0 million as of Q3 2025.
  • Indivior Pharmaceuticals' 5-year Total Debt high stood at $333.0 million for Q4 2024, and its period low was $240.0 million during Q4 2022.
  • Its 5-year average for Total Debt is $290.3 million, with a median of $322.0 million in 2025.
  • Its Total Debt has fluctuated over the past 5 years, first crashed by 82.64% in 2022, then soared by 3875.0% in 2024.
  • Over the past 5 years, Indivior Pharmaceuticals' Total Debt (Quarter) stood at $242.0 million in 2021, then fell by 0.83% to $240.0 million in 2022, then changed by 0.0% to $240.0 million in 2023, then skyrocketed by 38.75% to $333.0 million in 2024, then fell by 3.3% to $322.0 million in 2025.
  • Its Total Debt was $322.0 million in Q3 2025, compared to $326.0 million in Q2 2025 and $329.0 million in Q1 2025.